<DOC>
	<DOCNO>NCT00943826</DOCNO>
	<brief_summary>This 2 arm study investigate efficacy safety addition bevacizumab ( Avastin® ) current standard care ( multimodality therapy concurrent radiotherapy plus temozolomide follow adjuvant temozolomide ) compare current standard care alone . Patients randomly assign either Avastin® ( 10 mg/kg iv q2w ) placebo arm , combination radiation therapy ( total dose 60 Gy , administer 2 Gy fraction , 5 days/week ) plus temozolomide ( 75 mg/m2 po daily ) 6 week . After 4 week treatment break , patient continue receive Avastin® ( 10 mg/kg iv q2w ) placebo , plus temozolomide ( 150-200 mg/m2 po daily day 1-5 4 week cycle ) 6 cycle maintenance treatment . Following maintenance phase , Avastin® ( 15 mg/kg iv q3w ) placebo monotherapy continue . The anticipated time study treatment disease progression/unacceptable toxicity .</brief_summary>
	<brief_title>A Study Avastin® ( Bevacizumab ) Combination With Temozolomide Radiotherapy Patients With Newly Diagnosed Glioblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; newly diagnose glioblastoma ; World Health Organization ( WHO ) performance status &lt; =2 ; stable decrease corticosteroid dose within 5 day prior randomization . evidence recent hemorrhage postoperative magnetic resonance imaging ( MRI ) brain ; prior chemotherapy immunotherapy glioblastoma low grade astrocytomas ; prior radiotherapy brain ; clinically significant cardiovascular disease ; history &gt; =grade 2 hemoptysis within 1 month prior randomization ; previous centralize screen MethylguanineDNA methyltransferase ( MGMT ) status enrollment clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>